Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | KHK | P50053 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3196041 | 0.83 | HRH4 (0.41) | HRH4 | |
| SCHEMBL3197793 | 0.82 | HRH4 (0.41) | HRH4HSD11B1 | |
| SCHEMBL3202763 | 0.82 | HRH4 (0.41) | HRH4HSD11B1 | |
| SCHEMBL3213726 | 0.80 | HRH4 (0.53) | HRH4 | |
| SCHEMBL3206454 | 0.79 | HRH4 (0.43) | HRH4 | |
| SCHEMBL4400165 | 0.79 | LMNA (0.50) | HRH4 | |
| SCHEMBL4392402 | 0.79 | LMNA (0.50) | HRH4 | |
| SCHEMBL3206452 | 0.79 | HRH4 (0.42) | HRH4HSD11B1 | |
| SCHEMBL3204115 | 0.73 | HRH4 (0.52) | HRH4 | |
| SCHEMBL3205247 | 0.72 | HRH4 (0.43) | HRH4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | UCB PHARMA, S.A. (BE) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035863-A1 | 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions | HRH4, HRH2, HRH3 | HRH4 1/4885HSD11B1 3530/4885KHK 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.